
Karyopharm Therapeutics Investor Relations Material
Latest events

Q2 2025
Karyopharm Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Karyopharm Therapeutics Inc
Access all reports
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm Therapeutics develops therapeutic drug products based on an innovative drug delivery technology that has the potential to improve drug efficacy and safety in open label settings. Its lead product candidate, KPT-8602 for solid tumors and KPT-1203 for hematological malignancies, uses its proprietary Permeation Enhancing Sequence (PES)-based lipophilic doxorubicin (DOX) prodrug platform to develop novel therapeutics with potential clinical and commercial applications. Karyopharm Therapeutics is also developing KRN2300 to treat patients with multiple myeloma.
Key slides for Karyopharm Therapeutics Inc


Jefferies Global Healthcare Conference 2025
Karyopharm Therapeutics Inc


Jefferies Global Healthcare Conference 2025
Karyopharm Therapeutics Inc
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
KPTI
Country
🇺🇸 United States